According to the World Health Organization, there were almost 18 million patients living with cancer in 2020. It is estimated that over 14 million patients will require oncologic surgery in 2040. This is a 52% increase from 2018 estimations.¹ Due to the importance of a complete (R0) resection on survival and the increase in detection of early-stage disease, surgical resection remains an important treatment of solid tumors.^2,3 Achieving an R0 resection and identifying disease in lymph nodes or synchronous lesions has been shown repeatedly to improve oncologic outcomes and is a mainstay of curative-intent treatment.⁴ However, achieving these margins and finding residual disease during surgery remains a challenge for surgical oncologists. This is mainly due to the inability to see microscopic disease left behind and, at times, uncertainty about involvement of vital structures.